Sponsorship of Convergence enables you to reach the most influential pharmaceutical executives, biotech entrepreneurs, medical device innovators, academic researchers, and life sciences investors from the Northeast and beyond. Though two and a half days of exclusive networking, sponsors can interact directly with these key decision makers.
Thanks to our 2018 Sponsors:
Foley & Lardner LLP provides award-winning business and legal insight to clients across the country and around the world. Our exceptional client service, value, and innovative technology are continually recognized by our clients and the legal industry. Foley has been recognized in a survey of Fortune 1000 corporate counsel as an elite BTI Client Service 30 — one of only seven law firms to hold this distinction for more than 12 years (2015 BTI Client Service A-Team survey, The BTI Consulting Group, Wellesley, MA). In addition, Foley received 27 national Tier 1 rankings in the 2015 edition of U.S. News — Best Lawyers® “Best Law Firms,” and was named to the InformationWeek 500 list for seven of the past eight years for technological innovation that enhances business value. At Foley, we strive to create legal strategies that help you meet your needs today — and anticipate your challenges tomorrow.
Back Bay Life Science Advisors is strategic consulting and transaction advisory firm dedicated to uncovering the deepest business insights for our clients so that they can thrive in a competitive, dynamic environment.
Back Bay senior leadership is involved from conception through delivery to ensure that the recommendations are actionable and that the strategies make sense. Our team reflects a mixture of scientific, clinical and commercial expertise, and deep understanding of the financial/transactional markets. This gives our clients a unique perspective on the factors that drive success in development, commercialization and transactional execution.
These key factors equip us to develop the deep insights that lead to sustainable client advantages:
- Integrated scientific, clinical, commercial and transactional perspectives on growth opportunities
- In-depth understanding of high-value market, patient and physician segments
- Content-driven due diligence of attractive and feasible growth and investment strategies
- Analysis of critical value drivers, and recommendations for differentiated corporate expansion or exit opportunities